EarliPoint Health receives expanded FDA clearance for autism assessment in children up to age 8.

Read Release →

VB-MAPP and Objective Measurement: How Eye-Tracking Complements Verbal Behavior Assessment

On This Page

The VB-MAPP is one of the most widely used assessments in applied behavior analysis, and for good reason. It gives BCBAs a structured, developmentally sequenced picture of a child’s language and learning skills, and it doubles as a curriculum guide. None of what follows is an argument against it.

It’s an argument for what sits next to it.

VB-MAPP was built to answer one question extremely well: what skills does this child have, and what should we teach next? It was not built to answer a different question that payers, clinical directors, and families are asking more and more often: how is this child’s underlying development changing over time, measured objectively? Those are two different jobs. This guide covers what VB-MAPP measures, where its design draws the line, and how an objective developmental layer — including FDA-cleared eye-tracking measurement — can sit alongside it to make an assessment battery more complete.

What VB-MAPP Measures (and What it Was Designed to Do)

The Verbal Behavior Milestones Assessment and Placement Program (VB-MAPP) was developed by Mark Sundberg, Ph.D., BCBA-D, and is grounded in B.F. Skinner’s analysis of verbal behavior and the principles of applied behavior analysis. It is a criterion-referenced assessment, curriculum guide, and skill-tracking system for children with autism and other developmental or language delays.

It has five components:

  • Milestones Assessment — 170 learning and language milestones sampled across 16 skill areas, sequenced and balanced across three developmental levels up to roughly 48 months.
  • Barriers Assessment — 24 common language and learning barriers (problem behavior, instructional control, faulty mand or tact repertoires, and so on) that can impede progress.
  • Transition Assessment — 18 areas that summarize whether a child is ready to move to a less restrictive learning environment.
  • Task Analysis and Skills Tracking — a more granular breakdown supporting curriculum and IEP planning.
  • Placement and IEP Goals — guidance that turns the assessment into an intervention plan.

The 16 milestone areas include the verbal operants at the core of Skinner’s framework — mand (requesting), tact (labeling), intraverbal (conversational responding) — alongside listener responding, visual perceptual skills and matching-to-sample, play, social behavior, and the early academic repertoires.

How VB-MAPP is Scored

Scoring is deliberately simple. Each milestone receives a 0, 0.5, or 1: a 0 for an absent or incorrect response, a 0.5 for a partial response, and a 1 for an accurate, independent response. Those scores map onto three levels:

Level Developmental range Focus
Level 1 0–18 months Early mands, tacts, listener skills, play, imitation
Level 2 18–30 months Expanding language, listener responding, social play, early academics
Level 3 30–48 months Intraverbals, group skills, early reading/writing/math, complex language

A completed Milestones grid becomes a visual profile of the whole child — strengths, gaps, and a logical teaching sequence.

Where VB-MAPP Shows its Limits — by Design, Not as Criticism

Every assessment makes trade-offs. The most important thing to understand about VB-MAPP’s limits is that they are features of its design, not flaws. It was built for a specific purpose, and that purpose defines its edges.

It’s criterion-referenced, not norm-referenced. VB-MAPP compares a child to a set of developmental objectives, not to a normed population of same-age peers. That’s exactly right for curriculum planning — you want to know which skills to teach, not where the child ranks on a bell curve. But it means VB-MAPP does not produce the standardized scores that some payers and school systems expect from an outcome measure.

It tops out at roughly 48 months developmentally. The Milestones Assessment is sequenced to about a 48-month developmental ceiling. For early learners that range is a strength. For children whose repertoires exceed it, clinicians move to other tools.

Scoring depends on observation and clinician judgment. VB-MAPP is administered and scored by a BCBA or qualified clinician through direct testing and observation. That clinical expertise is the point — but it also introduces a degree of observer variability, and it makes the assessment time-intensive to administer fully.

It was never designed to be an objective biomarker. VB-MAPP tells you what a child can do. It was not built to quantify the underlying social-developmental processes that drive those skills, independent of who is doing the scoring.

These aren’t reasons to stop using VB-MAPP. They’re the reason a complementary layer exists.

The Case for Adding an Objective Developmental Layer

Two forces are pushing ABA toward more objective measurement, and neither has anything to do with whether VB-MAPP is a good tool.

The first is payer documentation. Requirements vary by payer, but practice-facing guidance suggests many plans ask for periodic progress reviews — often around every six months — and that reauthorization packages tend to be stronger when they include standardized assessment comparisons (pre/post scores on the same measures) alongside goal-mastery data (Praxis Notes). Standardized outcome measures that deliver objective, normed data on client growth appear to be growing more common in this context. Criterion-referenced tools like VB-MAPP demonstrate progress, but they weren’t built to serve as standardized outcome measures on their own.

The second is the limits of any single data stream. A skills assessment captures behavior at one point, filtered through one observer. Adding a second, objective stream — one that doesn’t depend on who administered it — gives a more complete and more defensible picture of how a child is developing.

That’s the gap an objective developmental layer fills. It doesn’t replace the skills picture. It sits beside it.

How Biomarker-Based Measurement Complements Verbal Behavior Assessment

This is where eye-tracking enters. The EarliPoint System is an FDA-cleared device that uses eye-tracking to objectively measure a child’s moment-by-moment social visual engagement — where and how long a child looks during carefully constructed video scenes, sampled many times per second.

Crucially, that looking behavior isn’t just a curiosity. In two large studies published in JAMA and JAMA Network Open in 2023, moment-by-moment looking behavior functioned as a robust, objective index of a child’s individual level of social disability, verbal ability, and nonverbal learning. The EarliPoint Severity Indices predicted 74.1% of the variance in social disability, 88.8% of verbal ability, and 77.9% of nonverbal cognitive ability against gold-standard reference measures.

Put the two tools side by side and the complement becomes clear:

VB-MAPP EarliPoint (objective layer)
What it measures Language, learning, and social skills against developmental milestones Objective indices of social, verbal, and nonverbal development via eye-tracking
Method Clinician observation + criterion-referenced scoring Automated eye-tracking biomarker, objective scoring
Output Skill milestones, barriers, placement guidance Quantitative severity indices, trackable over time
Strength Tells you what to teach next Tells you how underlying development is changing, observer-independent
Administration Variable; often 1–2 hours for a full administration across multiple sessions ~12–15 minutes, administered by trained staff

VB-MAPP answers “what skills does this child have, and what’s next?” The objective layer answers “how is this child’s social-developmental trajectory changing, in numbers that don’t depend on who measured them?” You need both questions answered. Neither tool answers the other’s question.

A Modern ABA Assessment Workflow — VB-MAPP Plus Objective Data Plus Clinical Observation

In practice, the three pieces fit together cleanly:

  • VB-MAPP drives curriculum and IEP goals — the day-to-day teaching plan.
  • Objective developmental measurement provides a standardized, repeatable baseline and a longitudinal trend line that’s easy to drop into a progress report.
  • Clinical observation and judgment integrates both, because no instrument replaces the clinician.

EarliPoint’s FDA clearance covers children 16 to 95 months of age — a range that overlaps the early-learner window where VB-MAPP does most of its work and extends well beyond it. That overlap is what makes longitudinal pairing possible: you can establish an objective developmental baseline early and re-measure it across the same reauthorization cycles in which you’re updating VB-MAPP.

Reauthorization Implications of Pairing VB-MAPP with Objective Data

This is where the pairing earns its keep operationally. A reauthorization reviewer wants to see that therapy is producing change and that continued services remain medically necessary. VB-MAPP shows skill acquisition. An objective measure adds a standardized, observer-independent index that’s repeatable on a periodic cadence — often around six months — that many payers tend to look for, though specifics vary by plan.

Two data streams pointing the same direction — skills mastered and objective developmental indices moving — make a stronger, harder-to-deny medical-necessity case than either alone. And because the objective measure doesn’t depend on the clinician scoring it, it’s less vulnerable to the “is this just rater drift?” question a reviewer might raise about any single observer-based tool.

Implementation: Bringing Both into Your Existing Workflow

You don’t need to rebuild your assessment process. A practical sequence:

  • Keep VB-MAPP where it is — initial assessment, curriculum design, and skills tracking.
  • Add an objective developmental baseline at intake for children in the cleared age range.
  • Re-measure on the reauthorization cycle so the objective trend line lands in the same six-month reviews.
  • Report both together — skill milestones from VB-MAPP, objective indices from the developmental layer, integrated by clinical narrative.

The administration burden is modest: the objective assessment runs about 12–15 minutes and is administered by trained staff rather than requiring additional BCBA hours.

If you’re rethinking your assessment stack, the broader principle is covered in our guide to objective outcomes measurement in ABA, and the payer side is covered in ABA reauthorization documentation. For the most commonly accepted standardized outcome measure today, see our complete Vineland guide and the Vineland and objective measurement.

Frequently Asked Questions

What are the limitations of VB-MAPP?

VB-MAPP is criterion-referenced rather than norm-referenced, so it doesn’t produce standardized scores that compare a child to same-age peers. Its milestones are sequenced to roughly a 48-month developmental ceiling, scoring depends on clinician observation and judgment, and it was designed as a curriculum and skills-tracking tool rather than a standardized outcome measure for payers. These are design choices, not defects — but they’re why an objective complement is useful.

Is VB-MAPP enough for an ABA reauthorization?

It depends on the payer. VB-MAPP demonstrates skill acquisition over time, which supports a reauthorization narrative. But many payers increasingly look for objective, standardized outcome data alongside criterion-referenced tools, and requirements vary by plan. Pairing VB-MAPP with a standardized measure — and, where appropriate, an objective developmental measure — produces a stronger medical-necessity case.

What does VB-MAPP not measure?

VB-MAPP measures language, learning, and social skills against developmental milestones. It is not a diagnostic instrument, it doesn’t produce norm-referenced standard scores, and it doesn’t provide an objective biomarker of social or developmental functioning that’s independent of observer judgment.

Can VB-MAPP be used for older children?

The Milestones Assessment is sequenced across a developmental range up to about 48 months, so it’s most informative for early learners. For children whose skills exceed that range, clinicians often move to tools such as the AFLS or the higher levels of other protocols. VB-MAPP remains the strongest fit for the early-learner window.

How is VB-MAPP scored?

Each milestone receives a 0, 0.5, or 1 — 0 for no or incorrect response, 0.5 for a partial response, and 1 for an accurate, independent response — across 170 milestones in 16 skill areas, sequenced over three developmental levels (0–18, 18–30, and 30–48 months).

Where this Leaves You

VB-MAPP is a strong tool doing exactly what it was built to do. The opportunity isn’t to replace it — it’s to add a second, objective stream of developmental data that answers a question VB-MAPP was never designed to answer, and that increasingly comes up in payer documentation conversations.

If you want to see how objective measurement pairs with VB-MAPP inside your existing workflow, connect with our provider team to talk through how it fits your caseload and your reauthorization cadence.

Angela Pagliaro, LBA, BCBA

Solutions Consultant

Angela is a Solutions Consultant at Earlipoint Health with expertise in applied behavior analysis and healthcare operations.

Angela Pagliaro, LBA, BCBA

Solutions Consultant

Angela is a Solutions Consultant at Earlipoint Health with expertise in applied behavior analysis and healthcare operations.

See how EarliPoint fits seamlessly into your clinical workflow.

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder